TY - JOUR
T1 - Carbimazole-induced agranulocytosis
T2 - Does antineutrophil cytoplasmic antibody have a role?
AU - Yip, G
AU - Ekinci, Elif
AU - Lee, S
AU - Jerums, George
AU - Grossmann, Mathis
PY - 2010/4/15
Y1 - 2010/4/15
N2 - Carbimazole is a drug that is widely used for hyperthyroid disorders, such as Graves' disease. Agranulocytosis is a rare idiosyncratic adverse reaction to the drug which is potentially fatal. This report describes a patient with a history of successfully treated pyoderma gangrenosum, who developed agranulocytosis 3 weeks after commencement of carbimazole for Graves' disease. It may give credence to the theory that implicates antineutrophil cytoplasmic antibodies in the pathogenesis of agranulocytosis induced by antithyroid drugs.
AB - Carbimazole is a drug that is widely used for hyperthyroid disorders, such as Graves' disease. Agranulocytosis is a rare idiosyncratic adverse reaction to the drug which is potentially fatal. This report describes a patient with a history of successfully treated pyoderma gangrenosum, who developed agranulocytosis 3 weeks after commencement of carbimazole for Graves' disease. It may give credence to the theory that implicates antineutrophil cytoplasmic antibodies in the pathogenesis of agranulocytosis induced by antithyroid drugs.
UR - http://www.scopus.com/inward/record.url?scp=77951107410&partnerID=8YFLogxK
U2 - 10.1111/j.1445-5994.2009.02143.x
DO - 10.1111/j.1445-5994.2009.02143.x
M3 - Article
VL - 40
SP - 300
EP - 303
JO - Internal Medicine Journal
JF - Internal Medicine Journal
SN - 1444-0903
IS - 4
ER -